Fig. 5From: Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat dietEffect of saroglitazar on different pathways AmiGO2 Gene Ontology was used to perform the GO enrichment and pathway analysis for the given, up or down- regulated genes. A. Saroglitazar treatment significantly down regulated the various genes involved in matrix degradation and extracellular matrix organization pathway, cell cycle pathway and platelet activation pathways, which were up regulated in disease control group animals. B. Saroglitazar treatment for 27 weeks also significantly up-regulated genes involved in mitochondrial fatty acid beta-oxidation, lipid metabolism, Bile acid/bile salt metabolism and alpha-linolenic acid (ALA) metabolism pathways. C. RTPCR data for relative mRNA expression of Igf2, Timp1, Cdc20, TGFβ, ADAM8, Col1a1, Col5a2, Elovl3, Acot1, Acot3, Fabp1, Slc10a1. Values are expressed as the means ± SEM (n = 3), * p < 0.05,**p < 0.01 vs. Disease Control Vehicle treated group using one way ANOVA followed by Dunnett’s multiple comparison testBack to article page